In 2025, the RUNX1 Research Program (RRP) continued its mission to fund research to prevent blood cancer in individuals with RUNX1 Familial Platelet Disorder (RUNX1-FPD). RRP awarded grants to investigators across leading academic medical centers, supporting research focused on disease mechanisms, clonal evolution, and blood cancer interception. Key funded programs included independent investigato… Read more
In 2025, the RUNX1 Research Program (RRP) continued its mission to fund research to prevent blood cancer in individuals with RUNX1 Familial Platelet Disorder (RUNX1-FPD). RRP awarded grants to investigators across leading academic medical centers, supporting research focused on disease mechanisms, clonal evolution, and blood cancer interception. Key funded programs included independent investigator grants, co-funded partnerships with Alexs Lemonade Stand Foundation, the American Cancer Society (new LEAP grant program), and support for several clinical trials (e.g. pilot study evaluating sirolimus as a preemptive intervention). RRP also continued operating its longitudinal RUNX1 Patient Data Hub, launching a centralized biospecimen bank (RUNX1 Tissue Bank), supporting patient recruitment for clinical research, and engaging the RUNX1-FPD patient and scientific community through its annual scientific conference, patient meeting, educational webinars, peer support groups, and patient-facing resources.
$1,894,463 spent
Where each dollar went · fiscal year 2025
Of every dollar it spent, 88¢ went to programs, 10¢ to management and 2¢ to fundraising.
Programs $1,894,463
Management $198,603
Fundraising $48,837
In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.
Spending on programs Not scored; America's Best needs 65%+
88%
Meets
Tax filings by year
Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.
Revenue$2,110,160Fiscal year 2025
Expenses$2,141,903Fiscal year 2025
Total assets$288,737Fiscal year 2025
Total liabilities$165,646Fiscal year 2025
Fiscal year ending December2025
Revenue$2,110,160
Expenses$2,141,903
Net income−$31,743
Net assets$123,091
Notable sources of revenue
Percent of total revenue
Contributions
$2,102,083
99.6%
Program services
$0
0.0%
Investment income
$5,795
0.3%
Other (net)
$2,282
0.1%
Assets / debt
Total assets
$288,737
Total liabilities
$165,646
Net assets
$123,091
Compensation
Not in our extract for this year.
Fiscal year ending December2024
Revenue$2,402,192
Expenses$2,352,337
Net income$49,855
Net assets$154,834
Notable sources of revenue
Percent of total revenue
Contributions
$2,394,842
99.7%
Program services
$0
0.0%
Investment income
$7,350
0.3%
Other (net)
$0
0.0%
Assets / debt
Total assets
$319,651
Total liabilities
$164,817
Net assets
$154,834
Compensation
Not in our extract for this year.
Fiscal year ending December2023
Revenue$1,549,012
Expenses$2,069,746
Net income−$520,734
Net assets$104,979
Notable sources of revenue
Percent of total revenue
Contributions
$1,542,823
99.6%
Program services
$0
0.0%
Investment income
$6,189
0.4%
Other (net)
$0
0.0%
Assets / debt
Total assets
$1,031,227
Total liabilities
$926,248
Net assets
$104,979
Compensation
Not in our extract for this year.
Fiscal year ending December2022
Revenue$670,719
Expenses$2,880,432
Net income−$2,209,713
Net assets$625,713
Notable sources of revenue
Percent of total revenue
Contributions
$670,719
100.0%
Program services
$0
0.0%
Investment income
$0
0.0%
Other (net)
$0
0.0%
Assets / debt
Total assets
$807,381
Total liabilities
$181,668
Net assets
$625,713
Compensation
Officers and key employees
$408,485
Share of expenses
14.2%
About this data
Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?